Arcturus Therapeutics Holdings Inc

Newest shelf

$500.0M

S-3 of 2025-12-30. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

At the market

$200.0M

Agreement of 2022-12-23. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

10.5 quarters

$191.5M on 2026-06-30 ÷ $18.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗